SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

21 marketing jobs

BeOne Medicines logo
5 months ago

Summer Internship, BeOne Corporate Brand and Reputation Intern

BeOne Medicines

USA (On-site)Full time
Previous
12
Next

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

21 jobs
BeOne Medicines logo

Summer Internship, BeOne Corporate Brand and Reputation Intern

BeOne Medicines

USA (On-site)

In-houseFull-timeIntern/new grad
5 months ago
Previous12
BeOne Medicines logo
BeOne Medicines

Summer Internship, BeOne Corporate Brand and Reputation Intern

USA (On-site)

Salary Not AvailableIntern/New GradFull time

Posted 5 months ago

  • Job
  • Company
  • People
  • Audience
  • News
  • Links

Job Summary

Drive Corporate Brand and Reputation support as an undergraduate intern, gaining exposure to end-to-end campaigns and storytelling across internal and external channels.

  • Own planning/execution support across communications channels.
  • Must-have: Bachelor’s degree pursuit in Communications or a related field.
  • Standout: Exposure to enterprise campaigns in a global oncology company.

Job Description

Responsibilities

  • Support planning and execution of the Corporate Brand and Reputation activities across internal and external communication channels
  • Assist with development and refinement of materials, including presentations, digital content, employee communications, and storytelling assets
  • Conduct research on audience insights, behavioral drivers, and best practices in corporate, purpose-driven, and healthcare communications
  • Track and summarize performance metrics, feedback, and engagement trends to inform optimization and future storytelling
  • Help coordinate content calendars, approvals, and versioning across cross-functional stakeholders
  • Participate in team meetings and working sessions, gaining exposure to end-to-end corporate campaign development
  • Contribute ideas grounded in communications, marketing, and behavioral science to support message clarity, resonance, and consistency

Requirements

  • Currently pursuing a bachelor’s degree in Communications, Marketing, Behavioral Science, Psychology, Sociology, Public Relations, or a related field

Preferred

  • familiarity with digital or social analytics tools is a plus
  • Strong written and verbal communication skills; ability to synthesize information and translate insights into clear takeaways; organized, proactive, and comfortable juggling multiple projects in a fast-paced environment; interest in healthcare, life sciences, or mission-driven organizations preferred

Benefits

  • Medical, Dental, Vision, 401(k), FSA/HSA, Life Insurance, Paid Time Off, and Wellness
BeOne Medicines logo

BeOne Medicines

4.1 Glassdoor

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.We all share the responsibility to report adverse events observed with our products so that they may be investigated, actioned, and communicated accordingly.To report an adverse event or side effect, please talk to your healthcare provider and contact us here: https://beonemedicines.com/contact-us/report-adverse-event/.

Founded in 2010
Cambridge, Massachusetts, USA
2.6K employees (125 in marketing)
beonemed.com
79% recommend to a friend
92% CEO approval

Marketing Team

Marketing Team Size
117 (4% of company)
Median Career Experience
19 years
Median Tenure
4 years
Marketing Roles Posted (Last 30 Days)
7

People

Founders / CEO

John V. Oyler
John V. Oyler
Founder & CEO
At the company for 16 years 1 month
Christine Riley Miller
Christine Riley Miller
Founder BeiGene Foundation
At the company for 5 years 1 month

HR / Recruitment

Blair Dugan Martin
Blair Dugan Martin
Executive Director, Commercial & Medical Affairs HRBP & Americas Head of Talent Acquisition
At the company for 9 years 5 months
yolanda yang
yolanda yang
Head of Talent Acquisition, APAC
At the company for 7 years 11 months

Marketing Leadership

Stefanie Schneider
Stefanie Schneider
Vice President, Hematology Marketing
At the company for 7 years 9 months
Stephen Ruenroeng
Stephen Ruenroeng
Vice President, Solid Tumor Marketing
At the company for 2 years 2 months
Blair Dugan Martin
Blair Dugan Martin
Executive Director, Commercial & Medical Affairs HRBP & Americas Head of Talent Acquisition
At the company for 9 years 5 months
Vincent Quan
Vincent Quan
Sr. Director, Head of Marketing, New Markets
At the company for 4 years 11 months

Headcount Trend

Current headcount: ~2.7K

Recent News

BeOne Medicines stock rating reiterated at Market Outperform by Citizens
Dec 11, 2025 • Investing.com
Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors
Dec 10, 2025 • PR Newswire
BeOne Medicines (ONC): Valuation Check After FDA Priority Review for Sonrotoclax in Mantle Cell Lymphoma
Dec 4, 2025 • simplywall.st
BeOne Medicines Continues To Execute In Q3 (NASDAQ:ONC)
Dec 4, 2025 • Seeking Alpha
BeOne’s sonrotoclax gains priority FDA review for mantle cell lymphoma
Nov 27, 2025 • Pharmaceutical Technology
How FDA Priority Review and Positive Phase 3 Data at BeOne Medicines (ONC) Has Changed Its Investment Story
Nov 27, 2025 • Yahoo Finance
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
Nov 20, 2025 • Yahoo Finance
BeOne Medicines stock price target raised to $408 from $395 at RBC Capital
Nov 18, 2025 • Investing.com
BeOne Medicines stock rises after positive trial results for cancer treatment
Nov 17, 2025 • Investing.com
We Think BeOne Medicines' (NASDAQ:ONC) Profit Is Only A Baseline For What They Can Achieve
Nov 17, 2025 • Yahoo Finance
Are Shares of BeOne Medicines Attractively Priced After Recent Cancer Therapeutics Collaboration?
Nov 14, 2025 • Yahoo Finance
BeOne Medicines ADR Earns Relative Strength Rating Upgrade
Nov 12, 2025 • Investor's Business Daily
Biotech Leader BeOne Medicines Eyes New Buy Point As Cancer Drug Sales Surge
Nov 11, 2025 • Investor's Business Daily
BeOne Medicines Ltd (ONC) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ...
Nov 11, 2025 • Yahoo Finance
How Strong BRUKINSA Sales and Patent Resolution at BeOne Medicines (ONC) Have Changed Its Investment Story
Nov 9, 2025 • Yahoo Finance
BeOne joins the Kat6 pack | ApexOnco - Clinical Trials news and analysis
Nov 7, 2025 • Oncology Pipeline
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
Nov 6, 2025 • Business Wire
Earnings call transcript: BeOne Medicines Q3 2025 beats expectations with strong EPS
Nov 6, 2025 • Investing.com
BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Nov 6, 2025 • Yahoo Finance
BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Nov 6, 2025 • Nasdaq
InSysBio to announce its collaboration with BeOne Medicines
Oct 29, 2025 • Yahoo Finance
John V. Oyler: From Vision to Global Transformation - The Journey of 15 years of BeOne Medicines
Oct 29, 2025 • Oncodaily
BeOne Medicines to Present at Upcoming Investor Conferences
Oct 28, 2025 • Yahoo Finance
How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment
Oct 27, 2025 • Investor's Business Daily
BeOne Medicines to expand cancer-drug offerings in Hong Kong
Oct 24, 2025 • South China Morning Post
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
Oct 22, 2025 • Yahoo Finance
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
Oct 21, 2025 • BioSpace
Callan Family Office LLC Takes Position in BeOne Medicines Ltd. - Sponsored ADR $ONC
Oct 17, 2025 • MarketBeat
BeOne’s sonrotoclax granted FDA Breakthrough Therapy designation
Oct 16, 2025 • The Pharma Letter
Does BeOne Medicines Stock Still Offer Opportunity After 74% YTD Surge?
Oct 15, 2025 • Yahoo Finance
A Look at BeOne Medicines (ONC) Valuation Following Breakthrough FDA and Project Orbis Milestones
Oct 15, 2025 • Yahoo Finance
Why BeOne Medicines (ONC) Is Up After FDA Breakthrough Tag and Project Orbis Review for Sonrotoclax
Oct 14, 2025 • Yahoo Finance
BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline (ONC)
Oct 14, 2025 • Seeking Alpha
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
Oct 13, 2025 • Yahoo Finance
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
Oct 13, 2025 • BioSpace
FDA grants breakthrough therapy status to BeOne’s lymphoma drug
Oct 13, 2025 • Investing.com
BeOne Medicines (ONC): Valuation Insight Following Positive Sonrotoclax Trial Results
Oct 12, 2025 • Sahm
BeOne Medicines AG stock hits 52-week high at 353.58 USD
Oct 2, 2025 • Investing.com
AbbVie, BeOne end BTK blood cancer drug patent fight
Oct 2, 2025 • Fierce Pharma
BeOne Medicines (ONC) Gains Barclays Overweight Rating Ahead of Key 2025 Data Readouts
Oct 1, 2025 • Yahoo Finance
Here’s Why BeOne Medicines Ltd. (ONC) Declined in Q2
Sep 29, 2025 • Yahoo Finance
BeOne Medicines AG (NASDAQ:ONC) About To Shift From Loss To Profit
Sep 24, 2025 • Yahoo Finance
John V. Oyler: BeOne Medicines Welcomes Global Leaders to San Carlos Office
Sep 24, 2025 • Oncodaily
Citizens JMP Maintains a Buy Rating on BeOne Medicines (ONC)
Sep 13, 2025 • Yahoo Finance
BeOne Medicines (ONC) Reports Positive Phase 1/2 Results for Sonrotoclax in MCL
Sep 11, 2025 • Yahoo Finance
BeOne Medicines (ONC): Assessing Valuation After Sonrotoclax Study Success and TEVIMBRA European Approval
Sep 9, 2025 • simplywall.st
Citizens JMP reiterates Market Outperform rating on BeOne Medicines stock
Sep 9, 2025 • Investing.com
Ivana Cattaneo: Excited to Lead European Government Affairs at BeOne Medicines
Sep 5, 2025 • Oncodaily
Positive Topline Results Seen for Sonrotoclax in R/R Mantle Cell Lymphoma
Sep 4, 2025 • The American Journal of Managed Care® (AJMC®)
BeOne reports topline MCL trial outcomes of BCL2 inhibitor
Sep 1, 2025 • Clinical Trials Arena
Assessing BeOne Medicines (ONC) Valuation Following Promising Sonrotoclax Trial Results and Regulatory Progress
Aug 30, 2025 • simplywall.st
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Aug 29, 2025 • BioSpace
BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients
Aug 29, 2025 • Yahoo Finance
BeOne Medicines posts trial win for lymphoma drug (ONC:NASDAQ)
Aug 29, 2025 • Seeking Alpha
BeOne plots accelerated approval for rare lymphoma drug after toplining Phase 1/2 data
Aug 29, 2025 • Endpoints News
Why Is BeOne Medicines Stock Gaining Friday? - BeOne Medicines (NASDAQ:ONC)
Aug 29, 2025 • Benzinga
BeOne Medicines stock rises after positive Phase 1/2 results
Aug 29, 2025 • Investing.com
BeOne's BCL2 drug hits primary endpoint, setting stage for filings to take up blood cancer mantle
Aug 29, 2025 • Fierce Biotech
BeOne's sonrotoclax heads to regulators after mantle cell lymphoma study win
Aug 29, 2025 • FirstWord Pharma
BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025
Aug 28, 2025 • Yahoo Finance
BeOne's Tevimbra notches fifth lung cancer approval in EU
Aug 28, 2025 • FirstWord Pharma
BeOne Medicines: Brukinsa's Leadership And Royalty Sale Signal A Stronger Future (NASDAQ:ONC)
Aug 26, 2025 • Seeking Alpha
BeOne cashes in its Imdelltra royalty | ApexOnco - Clinical Trials news and analysis
Aug 26, 2025 • Oncology Pipeline
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
Aug 25, 2025 • Yahoo Finance
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
Aug 25, 2025 • Business Wire
BeOne bags $885M upfront in Royalty deal on Amgen's lung cancer drug Imdelltra
Aug 25, 2025 • Fierce Pharma
BeOne Medicines stock rises after $950 million royalty deal with Royalty Pharma
Aug 25, 2025 • Investing.com
Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales
Aug 25, 2025 • BioPharma Dive
BeOne Medicines Announces $950 Million Royalty Purchase Agreement with Royalty Pharma for Imdelltra
Aug 25, 2025 • Pharmaceutical Executive
BeOne trades royalties on Amgen's Imdelltra for $885M upfront
Aug 25, 2025 • FirstWord Pharma
$950 Million Deal: BeOne Medicines Sells Royalty Rights for Breakthrough Lung Cancer Drug IMDELLTRA
Aug 25, 2025 • Stock Titan
BRUKINSA Tablet Approval Could Be a Game Changer for BeOne Medicines (ONC)
Aug 22, 2025 • Yahoo Finance
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
Aug 21, 2025 • Yahoo Finance
BeOne Medicines AG stock hits 52-week high at 314.99 USD
Aug 15, 2025 • Investing.com
BeOne Medicines posts 2nd-qtr revenue growth of 41%
Aug 13, 2025 • The Pharma Letter
BeOne Medicines Ltd (SHSE:688235) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Aug 7, 2025 • Yahoo Finance
John V. Oyler: Q2 2025 Marks Another Strong Quarter for BeOne Medicines
Aug 7, 2025 • Oncodaily
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
Aug 6, 2025 • TradingView
BeOne Medicines DRC earnings missed by $0.04, revenue topped estimates
Aug 6, 2025 • Investing.com
BeOne, now a Swiss company, widens Brukinsa's BTK lead over AstraZeneca's Calquence
Aug 6, 2025 • Fierce Pharma
CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication
Aug 5, 2025 • PMLiVE
BeOne Medicines’ BTK degrader gains EMA PRIME designation
Aug 1, 2025 • Pharmaceutical Technology
New antibody-drug conjugate detailed in Beone Medicines patent
Jul 31, 2025 • BioWorld MedTech
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
Jul 31, 2025 • Business Wire
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
Jul 28, 2025 • Business Wire
BeOne Medicines stock rises after positive EU opinion for lung cancer drug
Jul 28, 2025 • Investing.com
BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra
Jul 25, 2025 • Yahoo Finance
BeOne Medicines: Advancing Innovation in Cancer Treatment Across New Jersey and America
Jul 24, 2025 • ROI-NJ
BeOne Medicines stock reaches 52-week high at 294.41 USD
Jul 17, 2025 • Investing.com
BeOne Medicines stock price target raised to $349 from $311 at RBC Capital
Jul 16, 2025 • Investing.com
BeOne Medicines to Announce Q2 2025 Financial Results
Jul 16, 2025 • TipRanks
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
Jul 16, 2025 • Business Wire
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
Jul 16, 2025 • Yahoo Finance
EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer
Jul 16, 2025 • PMLiVE
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO Sells $7,044,470.76 in Stock
Jul 14, 2025 • MarketBeat
EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma
Jul 11, 2025 • Pharmaceutical Technology
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
Jul 9, 2025 • Business Wire
Stocks To Watch: BeOne Medicines ADR Sees RS Rating Rise To 83
Jul 8, 2025 • Investor's Business Daily
BeOne joins the subcutaneous crowd | ApexOnco - Clinical Trials news and analysis
Jul 4, 2025 • Oncology Pipeline
BeOne tries to repeat the inhibitor-degrader double | ApexOnco - Clinical Trials news and analysis
Jun 30, 2025 • Oncology Pipeline

Links

beonemed.comLinkedInX (Twitter)